Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

    NEXT STORY
    CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
    PREV STORY
    In vitro Diagnostics Market is Forecast to Rise at 4.5% CAGR and Reach USD 87.11 Billion by 2026; Launch of Altostar Molecular Diagnostics Workflow by Altona Diagnostics Gmbh Will Support Growth, says Fortune Business Insights
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Lawrence Lamb, Ph.D. Incysus Therapeutics Scientific Co-Founder to Present at 10th Annual Bioprocessing Summit

    NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company ...

    author_avatar
    NASDAQ Market News

    Brandywine Realty Trust Announces Third Quarter 2020 Results and Narrows 2020 Guidance

    author_avatar
    NASDAQ Market News

    BeiGene Announces Proposed Public Offering

    CAMBRIDGE, Mass. and BEIJING, Aug. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage ...

    author_avatar
    NASDAQ Market News